Nanoparticle-siRNA : a potential strategy for ovarian cancer therapy?
Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 14(2019), 15 vom: 01. Aug., Seite 2083-2100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aghamiri, Shahin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.05.2020 Date Revised 18.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2018-0379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29979850X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29979850X | ||
| 003 | DE-627 | ||
| 005 | 20231225101128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2018-0379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM29979850X | ||
| 035 | |a (NLM)31368405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aghamiri, Shahin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanoparticle-siRNA |b a potential strategy for ovarian cancer therapy? |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2020 | ||
| 500 | |a Date Revised 18.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a RNA interference | |
| 650 | 4 | |a codelivery system | |
| 650 | 4 | |a hyperthermia therapy | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a lipid-based delivery | |
| 650 | 4 | |a nanoparticle | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a photodynamic therapy | |
| 650 | 4 | |a polymeric-based siRNA delivery | |
| 650 | 4 | |a siRNA delivery systems | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 700 | 1 | |a Mehrjardi, Keyvan Fallah |e verfasserin |4 aut | |
| 700 | 1 | |a Shabani, Sasan |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavarz-Fathi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Kargar, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 14(2019), 15 vom: 01. Aug., Seite 2083-2100 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:15 |g day:01 |g month:08 |g pages:2083-2100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2018-0379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 15 |b 01 |c 08 |h 2083-2100 | ||